TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38008109

Group type: EXPERIMENTAL
Intervention: 72 mg ligelizumab
Number of subjects: 2057

Group type: EXPERIMENTAL
Intervention: 120 mg ligelizumab
Number of subjects: 2057

Group type: COMPARATOR
Intervention: 300 mg omalizumab
Number of subjects: 2057

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2057
Study: 38008305

Group type: EXPERIMENTAL
Intervention: Oral levonorgestrel emergency contraception with same-day etonogestrel implant insertion
Number of subjects: 160
Study: 38008698

Group type: EXPERIMENTAL
Intervention: Diet + exercise (LFN-exercise protocol)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 27
Study: 38008712

Group type: COMPARATOR
Intervention: Complex Training Group (CTG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Plyometric Training Group (PTG)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 42
Study: 38009088

Group type: EXPERIMENTAL
Intervention: Dual-task (DT) conditions involving a secondary cognitive task (visual discrimination, attention task, mental arithmetic) during motor activities (overground walking, semi-tandem stance, isometric knee extension)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Overground walking in wide vs. narrow lane conditions
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Static and dynamic motor activities assessed with high-density surface electromyography and electroencephalography
Number of subjects: 42
Study: 38009200

Group type: EXPERIMENTAL
Intervention: Pralsetinib
Number of subjects: 0
Study: 38009209

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38009241

Group type: EXPERIMENTAL
Intervention: donidalorsen 80 mg subcutaneously every 4 weeks (Q4W)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: donidalorsen 80 mg every 8 weeks (Q8W)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: donidalorsen
Number of subjects: 17
Study: 38009310

Group type: EXPERIMENTAL
Intervention: Highest tertile of systolic blood pressure variability (BPV)
Number of subjects: 13000

Group type: EXPERIMENTAL
Intervention: Higher systolic BPV
Number of subjects: 13000

Group type: EXPERIMENTAL
Intervention: Diastolic BPV
Number of subjects: 13000
Study: 38009546

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 12-week, home-based intervention based on individual and family self-management theory.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Attention Control Group (AC)
Number of subjects: 60
Study: 38009575

Group type: EXPERIMENTAL
Intervention: Mesh hernia repair
Number of subjects: 1241
Study: 38009662

Group type: EXPERIMENTAL
Intervention: Combination therapy (tremelimumab plus durvalumab)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sequential therapy (tremelimumab followed by durvalumab)
Number of subjects: 61
Study: 38009933

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Buprenorphine/Naloxone
Number of subjects: 52
Study: 38009966

Group type: EXPERIMENTAL
Intervention: Active (anodal) transcranial direct current stimulation (tDCS) targeting the mPFC during exposure therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS) during exposure therapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Exposure therapy (giving speeches to audiences in virtual reality)
Number of subjects: 31
Study: 38010035

Group type: EXPERIMENTAL
Intervention: Specialized care for ADPKD including pain/depression screening, cardiac manifestations, liver and pancreatic cysts, kidney stone management, and genetic counseling.
Number of subjects: 0
Study: 38010080

Group type: EXPERIMENTAL
Intervention: Probiotic intervention
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study: 38010108

Group type: COMPARATOR
Intervention: SAR443820 (DNL788)
Number of subjects: 0
Study: 38010254

Group type: EXPERIMENTAL
Intervention: ASP0892 (1 mg id)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ASP0892 (4 mg im)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ASP0892 (4 mg id)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ASP0892
Number of subjects: 51
Study: 38010261

Group type: EXPERIMENTAL
Intervention: Structured social communication assessment (CSBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naturalistic social communication assessment (MCX)
Number of subjects: 0
Study: 38010260

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily (q.d.)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Comparator EGFR-TKIs (gefitinib 250 mg q.d. or erlotinib 150 mg q.d.)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Observed RECIST PFS for osimertinib
Number of subjects: 320

Group type: COMPARATOR
Intervention: Observed RECIST PFS for comparator
Number of subjects: 320
Study: 38010394

Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day)
Number of subjects: 9
Study: 38010430

Group type: EXPERIMENTAL
Intervention: Eosinophilic Esophagitis Impact Questionnaire (EoE-IQ)
Number of subjects: 239
Study: 38010606

Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b at 250 μg plus standard of care (SOC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 60
Study: 38010656

Group type: EXPERIMENTAL
Intervention: Video education on neonatal resuscitation options
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38010661

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once daily for 52-week maintenance therapy
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg once daily for 52-week maintenance therapy
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: upadacitinib 45 mg once daily for 16 weeks during induction therapy
Number of subjects: 663
Study: 38010691

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 455
Study: 38010725

Group type: EXPERIMENTAL
Intervention: Personalized risk-reduction intervention (health coaching and nurse visits)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Personalized risk-reduction intervention
Number of subjects: 172
Study: 38010758

Group type: EXPERIMENTAL
Intervention: Self-reported Working Alliance Inventory (WAI) indicating a drop in alliance
Number of subjects: 58

Group type: COMPARATOR
Intervention: Randomly chosen sessions from the same treatment phase
Number of subjects: 58
Study: 38010773

Group type: EXPERIMENTAL
Intervention: Within-person elevations in negative affect
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Positive affect
Number of subjects: 92
Study: 38011030

Group type: EXPERIMENTAL
Intervention: Online Meditation Course
Number of subjects: 0
Study: 38011129

Group type: EXPERIMENTAL
Intervention: Preloaded combination nicotine replacement therapy (NRT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fast-acting nicotine replacement therapy (NRT) alone
Number of subjects: 200
Study: 38011131

Group type: EXPERIMENTAL
Intervention: [68Ga]FAPI-46 PET
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: [68Ga]FAPI-46 PET after neoadjuvant therapy (NAT)
Number of subjects: 60
Study: 38011138

Group type: EXPERIMENTAL
Intervention: Three exercise modalities
Number of subjects: 280
Study: 38011235

Group type: EXPERIMENTAL
Intervention: Exenatide (5 µg BID subcutaneous injection) for 5 days or until hospital discharge.
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard care.
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Exenatide (5 µg BID subcutaneous injection).
Number of subjects: 350
Study: 38011331

Group type: EXPERIMENTAL
Intervention: Angioplasty guidewire-assisted transseptal puncture (TSP)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Conventional Brockenbrough needle TSP
Number of subjects: 263
Study: 38011350

Group type: EXPERIMENTAL
Intervention: Provider training adaptations
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PrEP advertising adaptations
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PrEP safety information
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Role-playing in training
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Incorporation of side effects information in advertisements
Number of subjects: 25
Study: 38011420

Group type: EXPERIMENTAL
Intervention: edaravone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38011623

Group type: EXPERIMENTAL
Intervention: Asynchronous Telepsychiatry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synchronous Telepsychiatry
Number of subjects: 0
Study: 38011669

Group type: EXPERIMENTAL
Intervention: Conventional synthetic DMARDs in the UK (66.4%) vs continental Europe (44.9%)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Biologic DMARDs in the UK (36.4%) vs continental Europe (64.4%)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: CollaboRATE scores ≥4.5
Number of subjects: 503

Group type: COMPARATOR
Intervention: CollaboRATE scores <4.5
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: High levels of collaboration in face-to-face PsA consultations
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Mild disease activity with higher perceived collaboration
Number of subjects: 503
Study: 38011688

Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Heated intravenous (IV) fluids
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Heated irrigation fluids
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of forced-air warming and heated IV and irrigation fluids
Number of subjects: 120
Study: 38011704

Group type: EXPERIMENTAL
Intervention: In-vehicle HEPA filtration
Number of subjects: 14

Group type: COMPARATOR
Intervention: On-road air exposure (control)
Number of subjects: 14
Study: 38011739

Group type: EXPERIMENTAL
Intervention: Meditation-based lifestyle modification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38011750

Group type: EXPERIMENTAL
Intervention: Acceptance-Commitment Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38011922

Group type: EXPERIMENTAL
Intervention: High sensitivity cardiac troponin I assay
Number of subjects: 48282

Group type: EXPERIMENTAL
Intervention: High sensitivity cardiac troponin I assay (reclassified patients)
Number of subjects: 48282

Group type: EXPERIMENTAL
Intervention: High sensitivity cardiac troponin I assay (non-ischaemic myocardial injury)
Number of subjects: 48282
Study: 38011968

Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg) and Cetuximab (500, 400 or 300 mg/m2)
Number of subjects: 16
Study: 38011967

Group type: EXPERIMENTAL
Intervention: Single text message (TM1)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Multiple text messages (TM+)
Number of subjects: 200

Group type: COMPARATOR
Intervention: TM1-Continued (no further TM)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TM1 & MAPS (no further TM, up to 2 MAPS calls)
Number of subjects: 200

Group type: COMPARATOR
Intervention: TM+Continued (monthly text messages)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TM+ & MAPS (monthly text messages, plus up to 2 MAPS calls)
Number of subjects: 200
Study: 38011984

Group type: EXPERIMENTAL
Intervention: Nebulised 3% hypertonic saline (5 mL, three times a day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Normal saline (5 mL, three times a day)
Number of subjects: 140
Study: 38011992

Group type: EXPERIMENTAL
Intervention: Prehospital rule-out of NSTE-ACS using HEAR score and point-of-care troponin measurement
Number of subjects: 863
Study: 38011991

Group type: EXPERIMENTAL
Intervention: Type-1 CMD (INOCA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Type-4 CMD (CCS/PCI)
Number of subjects: 35
Study: 38012044

Group type: EXPERIMENTAL
Intervention: Practice facilitation intervention
Number of subjects: 90
Study: 38012137

Group type: EXPERIMENTAL
Intervention: Hybrid immunity or vaccination
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Infected but unvaccinated
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 2500
Study: 38012285

Group type: EXPERIMENTAL
Intervention: gosuranemab low-dose (125 mg q4w)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: gosuranemab intermediate-dose (600 mg q4w)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: gosuranemab high-dose (2000 mg q4w)
Number of subjects: 654

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: gosuranemab (all doses)
Number of subjects: 654
Study: 38012327

Group type: EXPERIMENTAL
Intervention: Cardiovascular risk management for 12 months
Number of subjects: 50
Study: 38012345

Group type: EXPERIMENTAL
Intervention: Multiphasic exercise prehabilitation intervention
Number of subjects: 0
Study: 38012413

Group type: EXPERIMENTAL
Intervention: Vegan diet (n=122)
Number of subjects: 244
Study: 38012450

Group type: EXPERIMENTAL
Intervention: Device-encapsulated pancreatic precursor cells derived from human embryonic stem cells, 2-3-fold higher cell doses, optimized membrane perforation pattern.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) and insulin dosing.
Number of subjects: 10
Study: 38012534

Group type: EXPERIMENTAL
Intervention: Sotatercept (starting dose 0.3 mg/kg; target dose 0.7 mg/kg)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 38012573

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) + Motivational Interviewing (MI) for AUD group
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) for all patients
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) for non-AUD group
Number of subjects: 242
Study: 38012644

Group type: EXPERIMENTAL
Intervention: Unconditional cash transfers (10,000 KES, ~$75 USD/month) and personalized infant feeding support from pregnancy to 7 months postpartum
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 38012647

Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach (SAIA)
Number of subjects: 3290

Group type: COMPARATOR
Intervention: Usual procedures (Control)
Number of subjects: 3290

Group type: EXPERIMENTAL
Intervention: SAIA (adjusted for provider training)
Number of subjects: 3290
Study: 38012682

Group type: EXPERIMENTAL
Intervention: Decitabine and ATRA (all-trans retinoic acid) combination therapy administered over 52 cycles
Number of subjects: 1
Study: 38012731

Group type: EXPERIMENTAL
Intervention: Prone position in early ARDS
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Prone position in persistent ARDS
Number of subjects: 57
Study: 38012740

Group type: EXPERIMENTAL
Intervention: Home rehabilitation training utilizing key identification technology for movement
Number of subjects: 104

Group type: COMPARATOR
Intervention: Supervised exercises in a hospital setting
Number of subjects: 104
Study: 38012751

Group type: EXPERIMENTAL
Intervention: mRNA vaccines
Number of subjects: 0
Study: 38012776

Group type: EXPERIMENTAL
Intervention: Videoconference-based adapted physical activity combined with endometriosis-based education program (6-month program, 45-120 min/week)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Videoconference-based adapted physical activity combined with endometriosis-based education program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 200
Study: 38012795

Group type: EXPERIMENTAL
Intervention: Single dose of amisulpride (100 mg)
Number of subjects: 120
Study: 38012820

Group type: EXPERIMENTAL
Intervention: AI-ECG analysis algorithm
Number of subjects: 9000
Study: 38012835

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 7.2 mg
Number of subjects: 35
Study: 38012862

Group type: EXPERIMENTAL
Intervention: HOPE candidates (D + kidneys)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Non-HOPE candidates (not listed for D + kidneys)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: HOPE candidates
Number of subjects: 324

Group type: COMPARATOR
Intervention: Non-HOPE candidates
Number of subjects: 324
Study: 38012899

Group type: EXPERIMENTAL
Intervention: Indocyanine green-near-infrared fluorescence imaging
Number of subjects: 42
Study: 38012959

Group type: COMPARATOR
Intervention: 4vHPV types
Number of subjects: 1871

Group type: COMPARATOR
Intervention: 9vHPV types
Number of subjects: 1871

Group type: COMPARATOR
Intervention: Cumulative IP incidence over 36 months (excluding anal canal; any 9vHPV type)
Number of subjects: 1871
Study: 38012987

Group type: EXPERIMENTAL
Intervention: Depressive symptoms in the second trimester (Edinburgh Postnatal Depression Scale score of ≥10)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Sustained first- and second-trimester depressive symptoms
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Second-trimester depressive symptoms in pregnancies with male fetuses
Number of subjects: 301

Group type: COMPARATOR
Intervention: First trimester depressive symptoms
Number of subjects: 301

Group type: COMPARATOR
Intervention: Third trimester depressive symptoms
Number of subjects: 301
Study: 38013135

Group type: EXPERIMENTAL
Intervention: Completely oral anticoagulation
Number of subjects: 5158

Group type: EXPERIMENTAL
Intervention: Sequential anticoagulation with DOACs
Number of subjects: 5158

Group type: EXPERIMENTAL
Intervention: Sequential anticoagulation with VKAs
Number of subjects: 5158

Group type: EXPERIMENTAL
Intervention: Completely parenteral anticoagulation
Number of subjects: 5158

Group type: EXPERIMENTAL
Intervention: Thrombolysis with DOACs
Number of subjects: 5158

Group type: COMPARATOR
Intervention: No anticoagulant treatment
Number of subjects: 5158
Study: 38013139

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38013387

Group type: EXPERIMENTAL
Intervention: Managers
Number of subjects: 10820

Group type: COMPARATOR
Intervention: Employees
Number of subjects: 10820

Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 10820

Group type: EXPERIMENTAL
Intervention: Managerial position
Number of subjects: 10820
Study: 38013523

Group type: EXPERIMENTAL
Intervention: Intermittent fasting (2 days fasting, 5 days ad libitum diet per week)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual healthy lifestyle (control group)
Number of subjects: 140
Study: 38013593

Group type: EXPERIMENTAL
Intervention: Transfusions
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Alloantibodies detection
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: RBC transfusions over decades
Number of subjects: 305
Study: 38013594

Group type: EXPERIMENTAL
Intervention: 4CMenB and MenACWY vaccines (two doses, given 1 month apart)
Number of subjects: 40
Study: 38014146

Group type: EXPERIMENTAL
Intervention: PRIMA subretinal neurostimulation system
Number of subjects: 5
Study: 38014462

Group type: EXPERIMENTAL
Intervention: Brief Observable Anxiety Sensitivity Treatment (BOAST) - a single clinician-led intervention session followed by a two-week ecological momentary intervention (EMI) via mobile app.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 38014479

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) and coordinated intervention including recommendations on polypharmacy, delirium, falls, nutrition, physical exercise, and a discharge plan
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) and coordinated intervention
Number of subjects: 821

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 821
Study: 38014659

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% once daily
Number of subjects: 0
Study: 38014673

Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 1394

Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 1394
Study: 38014676

Group type: EXPERIMENTAL
Intervention: Mechanical circulatory support (MCS) with Impella
Number of subjects: 406
Study: 38014691

Group type: EXPERIMENTAL
Intervention: High autoantibody concentrations targeting complement factor C3a receptor
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: High autoantibody concentrations targeting vascular endothelial growth factor receptor-2
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: High autoantibody concentrations targeting vascular endothelial growth factor B
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: High autoantibody levels
Number of subjects: 491
Study: 38014699

Group type: EXPERIMENTAL
Intervention: 12-week community-informed virtual world-based cardiac rehabilitation program
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 38014779

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study: 38015039

Group type: EXPERIMENTAL
Intervention: 68 Ga-FAPI-04 PET/CT
Number of subjects: 25
Study: 38015219

Group type: EXPERIMENTAL
Intervention: Direct mail (usual care plus educational materials and a mailed self-sampling kit)
Number of subjects: 31355

Group type: EXPERIMENTAL
Intervention: Opt-in (usual care plus educational materials and the option to request a kit)
Number of subjects: 31355

Group type: COMPARATOR
Intervention: Education (usual care plus educational materials)
Number of subjects: 31355
Study: 38015220

Group type: EXPERIMENTAL
Intervention: Toripalimab (240 mg) plus gemcitabine-cisplatin
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine-cisplatin
Number of subjects: 289
Study: 38015244

Group type: EXPERIMENTAL
Intervention: Susceptible (S) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-susceptible (NS) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Habituating (H) group
Number of subjects: 30
Study: 38015366

Group type: EXPERIMENTAL
Intervention: Elosan Cabin C1 treatment (8 sessions over 9 weeks)
Number of subjects: 192
Study: 38015442

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 301
Study: 38015467

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 11